Nov 08, 2023 / 01:30PM GMT
Richard J. Hawkins - Lumos Pharma, Inc. - Founder, CEO & Chairman
These are reports that all primary and secondary endpoints were met in both trials, and data from these trials provide supportive evidence to advance LUM-201 to a Phase 3 clinical trial. I'm going to commence by offering a summary outlining how we believe these data convincingly establish the validity of LUM-201 as a potential oral replacement for moderate PGHD patients, eliminating the need for daily and weekly injections.
Subsequently, I'll hand over to Discussion John C. McKew, our President and Chief Scientific Officer, who will provide a thorough examination of these results. So to begin, findings from our OraGrowtH210 study indicate that the LUM-201 dosage of 1.6 mg per kg resulted in annualized height velocities, or AHVs, of 8.2 centimeters a year at the 6-month mark and 8 centimeters a year at the 12-month mark.
These figures align with the historical growth rates observed in the moderate PGHD population. The difference in annualized height velocities at both the 6-month and 12-month time periods between the
Lumos Pharma Inc Phase 2 Topline Data and Q3 Report Transcript
Nov 08, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers